Investment Rating - The report maintains a "Recommended" investment rating for the company [1][8]. Core Views - The company's revenue growth is resilient, with significant contributions from coronary pathways and the gradual release of new electrophysiology products [4][5]. - The company achieved a revenue of 1.214 billion yuan in the first half of 2025, representing a year-over-year increase of 21.26%, and a net profit of 425 million yuan, up 24.11% year-over-year [3][4]. - The company is positioned as a leading player in the cardiovascular intervention field, benefiting from rapid growth trends in electrophysiology and vascular intervention sectors [8]. Financial Performance Summary - In the first half of 2025, the company reported a revenue of 1.214 billion yuan, with a year-over-year growth of 21.26%, and a net profit of 425 million yuan, reflecting a year-over-year increase of 24.11% [3]. - The company's gross margin for the first half of 2025 was 73.51%, with a slight increase in the second quarter to 73.87% [8]. - The company’s revenue from coronary intervention in the first half of 2025 reached 654 million yuan, marking a year-over-year growth of 30.02% [5]. - The company’s international sales in the first half of 2025 amounted to 143 million yuan, with a year-over-year increase of 23.84% [6]. Future Projections - The company is expected to achieve revenues of 2.066 billion yuan in 2024, 2.704 billion yuan in 2025, and 3.510 billion yuan in 2026, with respective year-over-year growth rates of 25.2%, 30.9%, and 29.8% [9][10]. - The projected net profit for 2025 is 884 million yuan, with a year-over-year growth of 31.3% [10]. - The company’s EPS is expected to grow from 4.77 yuan in 2024 to 6.27 yuan in 2025, and further to 8.10 yuan in 2026 [10].